Notice of Change to Key Dates Listed in PAR-23-274, "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)(UG3/UH3 Clinical Trial Required)"

Notice NOT-AG-23-058 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding